• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Ibrutinib Inhibitor

Scan QR to view Datasheet
Catalog # MBS575412
Unit / Price
Scan QR to view Datasheet
  5 mg  /  $135 +1 FREE 8GB USB
Structure
Product Name

Ibrutinib, Inhibitor

Popular Item
Full Product Name

Ibrutinib (PCI-32765)

Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Purity/Purification
0.98
CAS
936563-96-1
Formula
C25H24N6O2
Solubility
DMSO: 82 mg/mL (186.2 mM)
Ethanol: <1 mg/ml
Water: <1 mg/ml
Receptor (IC50)
BLK: 0.5 nM (cell free)
Bmx: 0.8 nM (cell free)
BTK: 0.5 nM (cell free)
CSK: 2.3 nM (cell free)
FGR: 2.3 nM (cell free)
BRK: 3.3 nM (cell free)
Kinase Assay
In vitro kinase IC50s were measured using 33P filtration binding assay after 1 h incubation of kinase, 33P-ATP, inhibitor, and substrate [0.2 mg/mL poly(EY)(4:1]. Assays were performed at Reaction Biology [1].
Cell Assay
CD20+ B and CD3+ T cells were purified by negative selection (RosetteSep, >90% purity) from buffy coat PBMCs and viably frozen in 10% DMSO. Cells were thawed at 37 degree C and maintained in growth media (RPMI media containing 10% FCS). B cells were stimulated with goat anti-human IgM F(ab?)2 (10 ug/mL) and T cells were stimulated with anti-CD3/CD28 coated beads ata 1:1 bead/cell ratio. Cells were stained with PE-CD69 and analyzed by flow cytometry, gating on viable lymphocytes. PCI-32765 at concentrations lower than 10 uM did not decrease B- or T-cell viability during the course of the experiment, although PCI-32765 did block the modest survival benefit of anti-IgM stimulation in B cells. For washout experiments, cells were rinsed three times in 10 volumes of growth media, a protocol that was confirmed to completely wash away inhibition of BCR signaling by PCI-29732, a reversible Btk inhibitor [1].

Cell line: Chronic lymphocytic leukemia (CLL) cells
Animal Experiment
Animal Model: MRL-Fas(lpr) lupus model and collagen-induced arthritis model.
Preparation and Storage
2 Years -80°C in solvent
3 years -20°C powder.
Other Notes
Small volumes of Ibrutinib inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
Ibrutinib inhibitor
MBS575412 (Ibrutinib is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM, modestly potent to Bmx, CSK, FGR, BRK HCK, less potent to EGFR, Yes , ErbB2, JAK3, etc.

Structure of Ibrutinib inhibitor
Ibrutinib inhibitor Structure image
Molecular Weight
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Diseases associated with Ibrutinib inhibitor
 Disease Name  Pubmed Publications
 Cancer Antibodies  > publications with Ibrutinib and Cancer
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000